{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T15:37:26Z","timestamp":1766158646920,"version":"3.37.3"},"reference-count":150,"publisher":"Bentham Science Publishers Ltd.","issue":"9","funder":[{"DOI":"10.13039\/501100008789","name":"West Bengal DST","doi-asserted-by":"publisher","award":["51(Sanc.)ST\/P\/S&T\/15G-11\/2018"],"award-info":[{"award-number":["51(Sanc.)ST\/P\/S&T\/15G-11\/2018"]}],"id":[{"id":"10.13039\/501100008789","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MRMC"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>COVID-19 is a public health emergency of international concern. Although considerable\nknowledge has been acquired with time about the viral mechanism of infection and mode of replication,\nyet no specific drugs or vaccines have been discovered against SARS-CoV-2 to date. There are\nfew small molecule antiviral drugs like Remdesivir and Favipiravir, which have shown promising results\nin different advanced stages of clinical trials. Chloroquinine, Hydroxychloroquine, and Lopinavir-\nRitonavir combination, although initially were hypothesized to be effective against SARSCoV-\n2, are now discontinued from the solidarity clinical trials. This review provides a brief description\nof their chemical syntheses along with their mode of action, and clinical trial results available on\nGoogle and in different peer-reviewed journals till 24th October 2020.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389557521666201222145842","type":"journal-article","created":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T04:07:43Z","timestamp":1608696463000},"page":"1123-1143","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Repurposed Antiviral Drugs for the Treatment of COVID-19: Syntheses, Mechanism of Infection and Clinical Trials"],"prefix":"10.2174","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4764-6314","authenticated-orcid":true,"given":"Subha Sankar","family":"Paul","sequence":"first","affiliation":[{"name":"Nanyang Technological University,Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1488-2003","authenticated-orcid":true,"given":"Goutam","family":"Biswas","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Cooch Behar Panchanan Barma University, Panchanan Nagar, Cooch Behar 736101,India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","volume":"579","author":"Wu F.","year":"2020","unstructured":"Wu F.; Zhao S.; Yu B.; Chen Y.M.; Wang W.; Song Z.G.; Hu Y.; Tao Z.W.; Tian J.H.; Pei Y.Y.; Yuan M.L.; Zhang Y.L.; Dai F.H.; Liu Y.; Wang Q.M.; Zheng J.J.; Xu L.; Holmes E.C.; Zhang Y.Z.; A new coronavirus associated with human respiratory disease in China. Nature 2020,579(7798),265-269","journal-title":"Nature"},{"journal-title":"WHO Coronavirus Disease (COVID-19) Dashboard","key":"ref=2","unstructured":"WHO Coronavirus Disease (COVID-19) Dashboard  https:\/\/covid19.who.int"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1101\/2020.05.13.20101253","volume":"99","author":"Ioannidis J.","year":"2021","unstructured":"Ioannidis J.; The infection fatality rate of COVID-19 inferred from seroprevalence data. Bull World Health Organ 2021,99,19-33F","journal-title":"Bull World Health Organ"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","volume":"395","author":"Lu R.","year":"2020","unstructured":"Lu R.; Zhao X.; Li J.; Niu P.; Yang B.; Wu H.; Wang W.; Song H.; Huang B.; Zhu N.; Bi Y.; Ma X.; Zhan F.; Wang L.; Hu T.; Zhou H.; Hu Z.; Zhou W.; Zhao L.; Chen J.; Meng Y.; Wang J.; Lin Y.; Yuan J.; Xie Z.; Ma J.; Liu W.J.; Wang D.; Xu W.; Holmes E.C.; Gao G.F.; Wu G.; Chen W.; Shi W.; Tan W.; Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet 2020,395(10224),565-574","journal-title":"Lancet"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"Zhu N.","year":"2020","unstructured":"Zhu N.; Zhang D.; Wang W.; Li X.; Yang B.; Song J.; Zhao X.; Huang B.; Shi W.; Lu R.; Niu P.; Zhan F.; Ma X.; Wang D.; Xu W.; Wu G.; Gao G.F.; Tan W.; China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020,382(8),727-733","journal-title":"N Engl J Med"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.abb3405","volume":"368","author":"Zhang L.","year":"2020","unstructured":"Zhang L.; Lin D.; Sun X.; Curth U.; Drosten C.; Sauerhering L.; Becker S.; Rox K.; Hilgenfeld R.; Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors. Science 2020,368(6489),409-412","journal-title":"Science"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/d41587-020-00005-z","volume":"38","author":"Hodgson J.","year":"2020","unstructured":"Hodgson J.; The pandemic pipeline. Nat Biotechnol 2020,38(5),523-532","journal-title":"Nat Biotechnol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.jacbts.2016.03.002","volume":"1","author":"Van Norman G.A.","year":"2016","unstructured":"Van Norman G.A.; Drugs, devices, and the FDA: Part 1. JACC Basic Transl Sci 2016,1(3),170-179","journal-title":"JACC Basic Transl Sci"},{"journal-title":"COVID-19 drug development Wikipedia,","year":"2020","key":"ref=9","unstructured":"COVID-19 drug development Wikipedia, 2020 https:\/\/en.wikipedia.org\/w\/index.php?title=COVID-19_drug_development"},{"journal-title":"Gilead announces results from phase 3 trial of investigational antiviral remdesivir in patients with severe COVID-19","key":"ref=10","unstructured":"Gilead announces results from phase 3 trial of investigational antiviral remdesivir in patients with severe COVID-19  https:\/\/www.gilead.com\/news-and-press\/press-room\/press-releases\/2020\/4\/gilead-announces-results-from-phase-3-trial-of-investigational-antiviral-remdesivir-in-patients-with-severe-covid-19"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"m4120","DOI":"10.1136\/bmj.m4120","author":"Mahase E.","year":"2020","unstructured":"Mahase E.; Covid-19: US approves remdesivir despite WHO trial showing lack of efficacy. BMJ 2020,m4120","journal-title":"BMJ"},{"journal-title":"WHO discontinues hydroxychloroquine and lopinavir\/ritonavir treatment arms for COVID-19","key":"ref=12","unstructured":"WHO discontinues hydroxychloroquine and lopinavir\/ritonavir treatment arms for COVID-19  https:\/\/www.who.int\/news-room\/detail\/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19"},{"key":"ref=13","author":"Turgeon J.","year":"2020","unstructured":"Turgeon J.; Michaud V.; Dow P.; Rihani S.R.A.; Deodhar M.; Arwood M.; Cicali B.;  Risk of drug-induced Long QT syndrome associated with the use of repurposed COVID-19 drugs: A systematic review 2020","journal-title":"Risk of drug-induced Long QT syndrome associated with the use of repurposed COVID-19 drugs: A systematic review"},{"journal-title":"Glenmark announces top-line results from Phase 3 clinical trial of favipiravir for COVID-19 treatment Express Pharma,","year":"2020","key":"ref=14","unstructured":"Glenmark announces top-line results from Phase 3 clinical trial of favipiravir for COVID-19 treatment Express Pharma, 2020 https:\/\/www.expresspharma.in\/covid19-updates\/glenmark-announces-top-line-results-from-phase-3-clinical-trial-of-favipiravir-for-covid-19-treatment\/"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","volume":"395","author":"Hung I.F-N.","year":"2020","unstructured":"Hung I.F-N.; Lung K-C.; Tso E.Y-K.; Liu R.; Chung T.W-H.; Chu M-Y.; Ng Y-Y.; Lo J.; Chan J.; Tam A.R.; Shum H-P.; Chan V.; Wu A.K-L.; Sin K-M.; Leung W-S.; Law W-L.; Lung D.C.; Sin S.; Yeung P.; Yip C.C-Y.; Zhang R.R.; Fung A.Y-F.; Yan E.Y-W.; Leung K-H.; Ip J.D.; Chu A.W-H.; Chan W-M.; Ng A.C-K.; Lee R.; Fung K.; Yeung A.; Wu T-C.; Chan J.W-M.; Yan W-W.; Chan W-M.; Chan J.F-W.; Lie A.K-W.; Tsang O.T-Y.; Cheng V.C-C.; Que T-L.; Lau C-S.; Chan K-H.; To K.K-W.; Yuen K-Y.; Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: An open-label, randomised, phase 2 trial. Lancet 2020,395(10238),1695-1704","journal-title":"Lancet"},{"key":"ref=16","author":"Wang Z.","year":"2020","unstructured":"Wang Z.; Yang B.; Li Q.; Wen L.; Zhang R.;  Clinical features of\n69 cases with coronavirus disease 2019 in Wuhan, China Clin Infect\nDis Off Publ Infect Dis Soc Am, 2020","journal-title":"Clinical features of\n69 cases with coronavirus disease 2019 in Wuhan, China Clin Infect\nDis Off Publ Infect Dis Soc Am,"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","volume":"30","author":"Wang M.","year":"2020","unstructured":"Wang M.; Cao R.; Zhang L.; Yang X.; Liu J.; Xu M.; Shi Z.; Hu Z.; Zhong W.; Xiao G.; Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020,30(3),269-271","journal-title":"Cell Res"},{"key":"ref=18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2019.116544","volume":"408","author":"Goyal G.","year":"2019","unstructured":"Goyal G.; Phukan A.C.; Hussain M.; Lal V.; Modi M.; Goyal M.K.; Sehgal R.; Sorting out difficulties in immunological diagnosis of neurocysticercosis: Development and assessment of real time loop mediated isothermal amplification of cysticercal DNA in blood. J Neurol Sci 2019,408","journal-title":"J Neurol Sci"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nature17180","volume":"531","author":"Warren T.K.","year":"2016","unstructured":"Warren T.K.; Jordan R.; Lo M.K.; Ray A.S.; Mackman R.L.; Soloveva V.; Siegel D.; Perron M.; Bannister R.; Hui H.C.; Larson N.; Strickley R.; Wells J.; Stuthman K.S.; Van Tongeren S.A.; Garza N.L.; Donnelly G.; Shurtleff A.C.; Retterer C.J.; Gharaibeh D.; Zamani R.; Kenny T.; Eaton B.P.; Grimes E.; Welch L.S.; Gomba L.; Wilhelmsen C.L.; Nichols D.K.; Nuss J.E.; Nagle E.R.; Kugelman J.R.; Palacios G.; Doerffler E.; Neville S.; Carra E.; Clarke M.O.; Zhang L.; Lew W.; Ross B.; Wang Q.; Chun K.; Wolfe L.; Babusis D.; Park Y.; Stray K.M.; Trancheva I.; Feng J.Y.; Barauskas O.; Xu Y.; Wong P.; Braun M.R.; Flint M.; McMullan L.K.; Chen S.S.; Fearns R.; Swaminathan S.; Mayers D.L.; Spiropoulou C.F.; Lee W.A.; Nichol S.T.; Cihlar T.; Bavari S.; Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 2016,531(7594),381-385","journal-title":"Nature"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1021\/acs.jmedchem.6b01594","volume":"60","author":"Siegel D.","year":"2017","unstructured":"Siegel D.; Hui H.C.; Doerffler E.; Clarke M.O.; Chun K.; Zhang L.; Neville S.; Carra E.; Lew W.; Ross B.; Wang Q.; Wolfe L.; Jordan R.; Soloveva V.; Knox J.; Perry J.; Perron M.; Stray K.M.; Barauskas O.; Feng J.Y.; Xu Y.; Lee G.; Rheingold A.L.; Ray A.S.; Bannister R.; Strickley R.; Swaminathan S.; Lee W.A.; Bavari S.; Cihlar T.; Lo M.K.; Warren T.K.; Mackman R.L.; Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of Ebola and emerging viruses. J Med Chem 2017,60(5),1648-1661","journal-title":"J Med Chem"},{"key":"ref=21","author":"Chun B.K.","year":"2017","unstructured":"Chun B.K.; Clarke M.O.N.H.; Doerffler E.; Hui H.C.; Jordan R.; Mackman R.L.; Parrish J.P.; Ray A.S.; Siegel D.;  Methods for\ttreating Filoviridae virus infections US9724360B2, 2017 https:\/\/patents.google.com\/patent\/US9724360B2\/en","journal-title":"Methods for\ttreating Filoviridae virus infections US9724360B2,"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1021\/acs.oprd.0c00172","volume":"24","author":"Vieira T.","year":"2020","unstructured":"Vieira T.; Stevens A.C.; Chtchemelinine A.; Gao D.; Badalov P.; Heumann L.; Development of a large-scale cyanation process using continuous flow chemistry en route to the synthesis of remdesivir. Org Process Res Dev 2020,24,2113-2121","journal-title":"Org Process Res Dev"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1021\/acs.oprd.0c00233","volume":"24","author":"De Savi C.","year":"2020","unstructured":"De Savi C.; Hughes D.L.; Kvaerno L.; Quest for a COVID-19 cure by repurposing small-molecule drugs: Mechanism of action, clinical development, synthesis at scale, and outlook for supply. Org Process Res Dev 2020,24,940-976","journal-title":"Org Process Res Dev"},{"key":"ref=24","author":"Wang M.","year":"2020","unstructured":"Wang M.; Zhang L.; Huo X.; Zhang Z.; Yuan Q.; Li P.; Chen J.; Zou Y.; Wu Z.; Zhang W.; Catalytic asymmetric synthesis of the anti\u2010COVID\u201019 drug Remdesivir. Angew Chem Int Ed 2020","journal-title":"Angew Chem Int Ed"},{"key":"ref=25","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal3653","volume":"9","author":"Sheahan T.P.","year":"2017","unstructured":"Sheahan T.P.; Sims A.C.; Graham R.L.; Menachery V.D.; Gralinski L.E.; Case J.B.; Leist S.R.; Pyrc K.; Feng J.Y.; Trantcheva I.; Bannister R.; Park Y.; Babusis D.; Clarke M.O.; Mackman R.L.; Spahn J.E.; Palmiotti C.A.; Siegel D.; Ray A.S.; Cihlar T.; Jordan R.; Denison M.R.; Baric R.S.; Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 2017,9(396)","journal-title":"Sci Transl Med"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","volume":"381","author":"Mulangu S.","year":"2019","unstructured":"Mulangu S.; Dodd L.E.; Davey R.T.; Tshiani Mbaya O.; Proschan M.; Mukadi D.; Lusakibanza Manzo M.; Nzolo D.; Tshomba Oloma A.; Ibanda A.; Ali R.; Coulibaly S.; Levine A.C.; Grais R.; Diaz J.; Lane H.C.; Muyembe-Tamfum J.J.; Sivahera B.; Camara M.; Kojan R.; Walker R.; Dighero-Kemp B.; Cao H.; Mukumbayi P.; Mbala-Kingebeni P.; Ahuka S.; Albert S.; Bonnett T.; Crozier I.; Duvenhage M.; Proffitt C.; Teitelbaum M.; Moench T.; Aboulhab J.; Barrett K.; Cahill K.; Cone K.; Eckes R.; Hensley L.; Herpin B.; Higgs E.; Ledgerwood J.; Pierson J.; Smolskis M.; Sow Y.; Tierney J.; Sivapalasingam S.; Holman W.; Gettinger N.; Vall\u00e9e D.; Nordwall J.; PALM Writing Group; PALM Consortium study team. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med 2019,381(24),2293-2303","journal-title":"N Engl J Med"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"6771","DOI":"10.1073\/pnas.1922083117","volume":"117","author":"de Wit E.","year":"2020","unstructured":"de Wit E.; Feldmann F.; Cronin J.; Jordan R.; Okumura A.; Thomas T.; Scott D.; Cihlar T.; Feldmann H.; Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci USA 2020,117(12),6771-6776","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"34218","DOI":"10.1074\/jbc.M806797200","volume":"283","author":"Tchesnokov E.P.","year":"2008","unstructured":"Tchesnokov E.P.; Obikhod A.; Schinazi R.F.; G\u00f6tte M.; Delayed chain termination protects the anti-hepatitis B virus drug entecavir from excision by HIV-1 reverse transcriptase. J Biol Chem 2008,283(49),34218-34228","journal-title":"J Biol Chem"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.celrep.2017.10.005","volume":"21","author":"Dulin D.","year":"2017","unstructured":"Dulin D.; Arnold J.J.; van Laar T.; Oh H-S.; Lee C.; Perkins A.L.; Harki D.A.; Depken M.; Cameron C.E.; Dekker N.H.; Signatures of nucleotide analog incorporation by an RNA-dependent RNA polymerase revealed using high-throughput magnetic tweezers. Cell Rep 2017,21(4),1063-1076","journal-title":"Cell Rep"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"4773","DOI":"10.1074\/jbc.AC120.013056","volume":"295","author":"Gordon C.J.","year":"2020","unstructured":"Gordon C.J.; Tchesnokov E.P.; Feng J.Y.; Porter D.P.; Gotte M.; The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem 2020,295(15),4773-4779","journal-title":"J Biol Chem"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","volume":"382","author":"Grein J.","year":"2020","unstructured":"Grein J.; Ohmagari N.; Shin D.; Diaz G.; Asperges E.; Castagna A.; Feldt T.; Green G.; Green M.L.; Lescure F-X.; Nicastri E.; Oda R.; Yo K.; Quiros-Roldan E.; Studemeister A.; Redinski J.; Ahmed S.; Bernett J.; Chelliah D.; Chen D.; Chihara S.; Cohen S.H.; Cunningham J.; D\u2019Arminio Monforte A.; Ismail S.; Kato H.; Lapadula G.; L\u2019Her E.; Maeno T.; Majumder S.; Massari M.; Mora-Rillo M.; Mutoh Y.; Nguyen D.; Verweij E.; Zoufaly A.; Osinusi A.O.; DeZure A.; Zhao Y.; Zhong L.; Chokkalingam A.; Elboudwarej E.; Telep L.; Timbs L.; Henne I.; Sellers S.; Cao H.; Tan S.K.; Winterbourne L.; Desai P.; Mera R.; Gaggar A.; Myers R.P.; Brainard D.M.; Childs R.; Flanigan T.; Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med 2020,382(24),2327-2336","journal-title":"N Engl J Med"},{"key":"ref=32","author":"Beigel J.H.","year":"2020","unstructured":"Beigel J.H.; Tomashek K.M.; Dodd L.E.; Mehta A.K.; Zingman B.S.; Kalil A.C.; Hohmann E.; Chu H.Y.; Luetkemeyer A.; Kline S.; Lopez de Castilla D.; Finberg R.W.; Dierberg K.; Tapson V.; Hsieh L.; Patterson T.F.; Paredes R.; Sweeney D.A.; Short W.R.; Touloumi G.; Lye D.C.; Ohmagari N.; Oh M.; Ruiz-Palacios G.M.; Benfield T.; F\u00e4tkenheuer G.; Kortepeter M.G.; Atmar R.L.; Creech C.B.; Lundgren J.; Babiker A.G.; Pett S.; Neaton J.D.; Burgess T.H.; Bonnett T.; Green M.; Makowski M.; Osinusi A.; Nayak S.; Lane H.C.; Remdesivir for the treatment of COVID-19 \u2014 Final report. N Engl J Med 2020","journal-title":"N Engl J Med"},{"key":"ref=33","doi-asserted-by":"publisher","DOI":"10.1101\/2020.10.15.20209817","year":"2020","unstructured":"WHO Solidarity trial consortium. H. Pan, R. Peto, Q.A. Karim, M. Alejandria, A.M. Henao-Restrepo, C.H. Garc\u00eda, M.-P. Kieny, R. Malekzadeh, S. Murthy, M.-P. Preziosi, S. Reddy, M.R. Periago, V. Sathiyamoorthy, J.-A. R\u00f8ttingen, S. Swaminathan, as the members of the Writing Committee, assume responsibility for the content and integrity of this article, repurposed antiviral drugs for COVID-19 \u2013interim WHO SOLIDARITY trial results, Infectious Diseases (except. HIV AIDS (Auckl) 2020","journal-title":"HIV AIDS (Auckl)"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s40261-018-0656-y","volume":"38","author":"Plantone D.","year":"2018","unstructured":"Plantone D.; Koudriavtseva T.; Current and future use of chloroquine and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases: A mini-review. Clin Drug Investig 2018,38(8),653-671","journal-title":"Clin Drug Investig"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","volume":"6","author":"Liu J.","year":"2020","unstructured":"Liu J.; Cao R.; Xu M.; Wang X.; Zhang H.; Hu H.; Li Y.; Hu Z.; Zhong W.; Wang M.; Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 2020,6,16","journal-title":"Cell Discov"},{"key":"ref=36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105945","volume":"55","author":"Sahraei Z.","year":"2020","unstructured":"Sahraei Z.; Shabani M.; Shokouhi S.; Saffaei A.; Aminoquinolines against coronavirus disease 2019 (COVID-19): Chloroquine or hydroxychloroquine. Int J Antimicrob Agents 2020,55(4)","journal-title":"Int J Antimicrob Agents"},{"key":"ref=37","author":"Chen Z.","year":"2020","unstructured":"Chen Z.; Hu J.; Zhang Z.; Jiang S.; Han S.; Yan D.; Zhuang R.; Hu B.; Zhang Z.;  Efficacy of hydroxychloroquine in patients with COVID-19: Results of a randomized clinical trial 2020","journal-title":"Efficacy of hydroxychloroquine in patients with COVID-19: Results of a randomized clinical trial"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S1473-3099(06)70361-9","volume":"6","author":"Savarino A.","year":"2006","unstructured":"Savarino A.; Di Trani L.; Donatelli I.; Cauda R.; Cassone A.; New insights into the antiviral effects of chloroquine. Lancet Infect Dis 2006,6(2),67-69","journal-title":"Lancet Infect Dis"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/B978-044452166-8\/50037-6","author":"Vardanyan R.S.","year":"2006","unstructured":"Vardanyan R.S.; Hruby V.J.;  Drugs for treating protozoan infections Synth Essent Drugs 2006,559-582","journal-title":"Drugs for treating protozoan infections Synth Essent Drugs"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1021\/ja01211a020","volume":"68","author":"Price C.C.","year":"1946","unstructured":"Price C.C.; Roberts R.M.; The synthesis of 4-hydroxyquinolines; through ethoxymethylene malonic ester. J Am Chem Soc 1946,68,1204-1208","journal-title":"J Am Chem Soc"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1021\/ja01205a036","volume":"68","author":"Surrey A.R.","year":"1946","unstructured":"Surrey A.R.; Hammer H.F.; Some 7-substituted 4-aminoquinoline derivatives. J Am Chem Soc 1946,68,113-116","journal-title":"J Am Chem Soc"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"4513","DOI":"10.1021\/ja01138a014","volume":"74","author":"Johnson W.S.","year":"1952","unstructured":"Johnson W.S.; Buell B.G.; A new synthesis of chloroquine. J Am Chem Soc 1952,74,4513-4516","journal-title":"J Am Chem Soc"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1021\/ja01212a061","volume":"68","author":"Elderfield R.C.","year":"1946","unstructured":"Elderfield R.C.; Gensler W.J.; Brody F.; Head J.D.; Dickerman S.C.; Wiederhold L.; Kremer C.B.; Hageman H.A.; Kreysa F.J.; Griffing J.M.; Kupchan S.M.; Newman B.; Maynard J.T.; Synthesis of l-alkylamino-4-bromopentane derivatives and of other amino halides. J Am Chem Soc 1946,68,1579-1584","journal-title":"J Am Chem Soc"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1021\/ja01160a116","volume":"72","author":"Surrey A.R.","year":"1950","unstructured":"Surrey A.R.; Hammer H.F.; The preparation of 7-Chloro-4-(4-(N-ethyl-N-\u03b2-hydroxyethylamino)-1- methylbutylamino)-quinoline and related compounds. J Am Chem Soc 1950,72,1814-1815","journal-title":"J Am Chem Soc"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"10787","DOI":"10.1128\/JVI.75.22.10787-10799.2001","volume":"75","author":"Mackenzie J.M.","year":"2001","unstructured":"Mackenzie J.M.; Westaway E.G.; Assembly and maturation of the flavivirus Kunjin virus appear to occur in the rough endoplasmic reticulum and along the secretory pathway, respectively. J Virol 2001,75(22),10787-10799","journal-title":"J Virol"},{"key":"ref=46","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200111230-00002","author":"Savarino A.","unstructured":"Savarino A.; Gennero L.; Chen H.C.; Serrano D.; Malavasi F.; Boelaert J.R.; Sperber K.;  Anti-HIV effects of chloroquine: Mechanisms\nof inhibition and spectrum of activity AIDS, 2001,\n15(17), 2221-2229  https:\/\/journals.lww.com\/aidsonline\/Fulltext\/2001\/11230\/Anti_HIV_effects_of_chloroquine__mechanisms_of.2.aspx","journal-title":"Anti-HIV effects of chloroquine: Mechanisms\nof inhibition and spectrum of activity AIDS, 2001,\n15(17), 2221-2229"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/S1473-3099(03)00806-5","volume":"3","author":"Savarino A.","year":"2003","unstructured":"Savarino A.; Boelaert J.R.; Cassone A.; Majori G.; Cauda R.; Effects of chloroquine on viral infections: An old drug against today\u2019s diseases? Lancet Infect Dis 2003,3(11),722-727","journal-title":"Lancet Infect Dis"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/s41565-020-0674-9","volume":"15","author":"Hu T.Y.","year":"2020","unstructured":"Hu T.Y.; Frieman M.; Wolfram J.; Insights from nanomedicine into chloroquine efficacy against COVID-19. Nat Nanotechnol 2020,15(4),247-249","journal-title":"Nat Nanotechnol"},{"key":"ref=49","first-page":"4901","volume":"158","author":"Jeong J.Y.","year":"1997","unstructured":"Jeong J.Y.; Jue D.M.;  Chloroquine inhibits processing of tumor\nnecrosis factor in lipopolysaccharide-stimulated RAW 2647 macrophages\nJ Immunol, 1997,158(10),4901-4907","journal-title":"Chloroquine inhibits processing of tumor\nnecrosis factor in lipopolysaccharide-stimulated RAW 2647 macrophages\nJ Immunol,"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S0306-3623(97)00269-3","volume":"30","author":"Bondeson J.","year":"1998","unstructured":"Bondeson J.; Sundler R.; Antimalarial drugs inhibit phospholipase A2 activation and induction of interleukin 1beta and tumor necrosis factor alpha in macrophages: Implications for their mode of action in rheumatoid arthritis. Gen Pharmacol 1998,30(3),357-366","journal-title":"Gen Pharmacol"},{"author":"van den Borne B.E.","key":"ref=51","unstructured":"van den Borne B.E.; Dijkmans B.A.; de Rooij H.H.; le Cessie S.; Verweij C.L.;  Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells. J. Rheumatol., 1997, 24(1), 55-60."},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"R1058","DOI":"10.1152\/ajpregu.1998.274.4.R1058","volume":"274","author":"Karres I.","year":"1998","unstructured":"Karres I.; Kremer J.P.; Dietl I.; Steckholzer U.; Jochum M.; Ertel W.; Chloroquine inhibits proinflammatory cytokine release into human whole blood. Am J Physiol 1998,274(4),R1058-R1064","journal-title":"Am J Physiol"},{"author":"Picot S.","key":"ref=53","unstructured":"Picot S.; Peyron F.; Donadille A.; Vuillez J.P.; Barbe G.; Ambroise-Thomas P.;  Chloroquine-induced inhibition of the production of TNF, but not of IL-6, is affected by disruption of iron metabolism. Immunology, 1993, 80(1), 127-133."},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.4049\/jimmunol.165.3.1534","volume":"165","author":"Weber S.M.","year":"2000","unstructured":"Weber S.M.; Levitz S.M.; Chloroquine interferes with lipopolysaccharide-induced TNF-alpha gene expression by a nonlysosomotropic mechanism. J Immunol 2000,165(3),1534-1540","journal-title":"J Immunol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1046\/j.0019-2805.2001.01339.x","volume":"105","author":"Jeong J-Y.","year":"2002","unstructured":"Jeong J-Y.; Choi J.W.; Jeon K-I.; Jue D-M.; Chloroquine decreases cell-surface expression of tumour necrosis factor receptors in human histiocytic U-937 cells. Immunology 2002,105(1),83-91","journal-title":"Immunology"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1089\/jir.2014.0038","volume":"35","author":"Wang L-F.","year":"2015","unstructured":"Wang L-F.; Lin Y-S.; Huang N-C.; Yu C-Y.; Tsai W-L.; Chen J-J.; Kubota T.; Matsuoka M.; Chen S-R.; Yang C-S.; Lu R-W.; Lin Y-L.; Chang T-H.; Hydroxychloroquine-inhibited dengue virus is associated with host defense machinery. J Interferon Cytokine Res 2015,35(3),143-156","journal-title":"J Interferon Cytokine Res"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.dsx.2020.03.011","volume":"14","author":"Singh A.K.","year":"2020","unstructured":"Singh A.K.; Singh A.; Shaikh A.; Singh R.; Misra A.; Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. Diabetes Metab Syndr 2020,14(3),241-246","journal-title":"Diabetes Metab Syndr"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1080\/15548627.2018.1474314","volume":"14","author":"Mauthe M.","year":"2018","unstructured":"Mauthe M.; Orhon I.; Rocchi C.; Zhou X.; Luhr M.; Hijlkema K-J.; Coppes R.P.; Engedal N.; Mari M.; Reggiori F.; Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy 2018,14(8),1435-1455","journal-title":"Autophagy"},{"key":"ref=59","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105938","volume":"55","author":"Devaux C.A.","year":"2020","unstructured":"Devaux C.A.; Rolain J-M.; Colson P.; Raoult D.; New insights on the antiviral effects of chloroquine against coronavirus: What to expect for COVID-19? Int J Antimicrob Agents 2020,55(5)","journal-title":"Int J Antimicrob Agents"},{"key":"ref=60","doi-asserted-by":"publisher","DOI":"10.1016\/j.msec.2020.110669","volume":"110","author":"Lv P.","year":"2020","unstructured":"Lv P.; Zhu L.; Yu Y.; Wang W.; Liu G.; Lu H.; Effect of NaOH concentration on antibacterial activities of Cu nanoparticles and the antibacterial mechanism. Mater Sci Eng C 2020,110","journal-title":"Mater Sci Eng C"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/acem.14005","volume":"27","author":"Chowdhury M.S.","year":"2020","unstructured":"Chowdhury M.S.; Rathod J.; Gernsheimer J.; A rapid systematic review of clinical trials utilizing chloroquine and hydroxychloroquine as a treatment for COVID-19. Acad Emerg Med 2020,27(6),493-504","journal-title":"Acad Emerg Med"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1001\/jamainternmed.2020.6319","volume":"181","author":"Abella B.S.","year":"2020","unstructured":"Abella B.S.; Jolkovsky, E.L.; Biney, B.T.; Uspal, J.E.; Hyman, M.C.; Frank, I.; Hensley, S.E.; Gill, S.; Vogl, D.T.; Maillard, I.; Babushok, D.V.; Huang, A.C.; Nasta, S.D.; Walsh, J.C.; Wiletyo, E.P.; Gimotty, P.A.; Milone, M.C.; Amaravadi, R.K. and the prevention and treatment of COVID-19 with hydroxychloroquine (PATCH) investigators. Efficacy and safety of hydroxychloroquine vs placebo for pre-exposure SARS-CoV-2 prophylaxis among health care workers: A randomized clinical trial. JAMA Intern Med 2020,181(2),195-202","journal-title":"JAMA Intern Med"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1128\/AAC.46.4.977-981.2002","volume":"46","author":"Furuta Y.","year":"2002","unstructured":"Furuta Y.; Takahashi K.; Fukuda Y.; Kuno M.; Kamiyama T.; Kozaki K.; Nomura N.; Egawa H.; Minami S.; Watanabe Y.; Narita H.; Shiraki K.; In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother 2002,46(4),977-981","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1128\/AAC.49.3.981-986.2005","volume":"49","author":"Furuta Y.","year":"2005","unstructured":"Furuta Y.; Takahashi K.; Kuno-Maekawa M.; Sangawa H.; Uehara S.; Kozaki K.; Nomura N.; Egawa H.; Shiraki K.; Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 2005,49(3),981-986","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.antiviral.2009.02.198","volume":"82","author":"Furuta Y.","year":"2009","unstructured":"Furuta Y.; Takahashi K.; Shiraki K.; Sakamoto K.; Smee D.F.; Barnard D.L.; Gowen B.B.; Julander J.G.; Morrey J.D.; T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res 2009,82(3),95-102","journal-title":"Antiviral Res"},{"year":"2001","author":"Egawa H.","key":"ref=66","unstructured":"Egawa H.; Furuta Y.;   Nitrogenous heterocyclic carboxamide derivatives or salts thereof and antiviral agents containing both. EP1112743A1, 2001 https:\/\/patents.google.com\/patent\/EP1112743A1\/ja"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1007\/s11696-017-0208-6","volume":"71","author":"Liu F.L.","year":"2017","unstructured":"Liu F.L.; Li C.Q.; Xiang H.Y.; Feng S.; A practical and step-economic route to Favipiravir. Chem Pap 2017,71,2153-2158","journal-title":"Chem Pap"},{"author":"Jordis U.","key":"ref=68","doi-asserted-by":"publisher","unstructured":"Jordis U.; Beldar S.;  Synthetic studies towards the antiviral pyrazine derivative T-705. Proc. 13th Int. Electron. Conf. Synth. Org. Chem., MDPI, Sciforum.net, 2009, p. 223.","DOI":"10.3390\/ecsoc-13-00223"},{"key":"ref=69","author":"Tamio H.","year":"2010","unstructured":"Tamio H.; Naoki N.; Hiraoki K.; Takuya K.;  Method for producing dichloropyrazine derivative WO2010087117A1, 2010 https:\/\/patents.google.com\/patent\/WO2010087117A1\/en","journal-title":"Method for producing dichloropyrazine derivative WO2010087117A1,"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s11696-018-0654-9","volume":"73","author":"Guo Q.","year":"2019","unstructured":"Guo Q.; Xu M.; Guo S.; Zhu F.; Xie Y.; Shen J.; The complete synthesis of favipiravir from 2-aminopyrazine. Chem Pap 2019,73,1043-1051","journal-title":"Chem Pap"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10593-020-02715-3","volume":"56","author":"Titova Y.A.","year":"2020","unstructured":"Titova Y.A.; Fedorova O.V.; Favipiravir - a modern antiviral drug: Synthesis and modifications. Chem Heterocycl Compd (N Y) 2020,56,1-4","journal-title":"Chem Heterocycl Compd (N Y)"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"58","DOI":"10.5582\/ddt.2020.01012","volume":"14","author":"Dong L.","year":"2020","unstructured":"Dong L.; Hu S.; Gao J.; Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther 2020,14(1),58-60","journal-title":"Drug Discov Ther"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2183\/pjab.93.027","volume":"93","author":"Furuta Y.","year":"2017","unstructured":"Furuta Y.; Komeno T.; Nakamura T.; Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad, Ser B, Phys Biol Sci 2017,93(7),449-463","journal-title":"Proc Jpn Acad, Ser B, Phys Biol Sci"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.bbrc.2012.07.034","volume":"424","author":"Rocha-Pereira J.","year":"2012","unstructured":"Rocha-Pereira J.; Jochmans D.; Dallmeier K.; Leyssen P.; Nascimento M.S.J.; Neyts J.; Favipiravir (T-705) inhibits in vitro norovirus replication. Biochem Biophys Res Commun 2012,424(4),777-780","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=75","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0068347","volume":"8","author":"Jin Z.","year":"2013","unstructured":"Jin Z.; Smith L.K.; Rajwanshi V.K.; Kim B.; Deval J.; The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5\u2032-triphosphate towards influenza A virus polymerase. PLoS One 2013,8(7)","journal-title":"PLoS One"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2183\/pjab.93.027","volume":"93","author":"Furuta T.Y.","year":"2017","unstructured":"Furuta T.Y.; Komeno T.; Nakamuba T.; Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad, Ser B, Phys Biol Sci 2017,93,449-463","journal-title":"Proc Jpn Acad, Ser B, Phys Biol Sci"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1128\/JVI.02346-12","volume":"87","author":"Baranovich T.","year":"2013","unstructured":"Baranovich T.; Wong S-S.; Armstrong J.; Marjuki H.; Webby R.J.; Webster R.G.; Govorkova E.A.; T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. J Virol 2013,87(7),3741-3751","journal-title":"J Virol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.3390\/ijms21072657","volume":"21","author":"Tu Y-F.","year":"2020","unstructured":"Tu Y-F.; Chien C-S.; Yarmishyn A.A.; Lin Y-Y.; Luo Y-H.; Lin Y-T.; Lai W-Y.; Yang D-M.; Chou S-J.; Yang Y-P.; Wang M-L.; Chiou S-H.; A review of SARS-CoV-2 and the ongoing clinical trials. Int J Mol Sci 2020,21(7),2657","journal-title":"Int J Mol Sci"},{"key":"ref=79","author":"Chen C.","year":"2020","unstructured":"Chen C.; Zhang Y.; Huang J.; Yin P.; Cheng Z.; Wu J.; Chen S.; Zhang Y.; Chen B.; Lu M.; Luo Y.; Ju L.; Zhang J.; Wang X.;  Favipiravir versus arbidol for COVID-19: A randomized clinical trial 2020","journal-title":"Favipiravir versus arbidol for COVID-19: A randomized clinical trial"},{"key":"ref=80","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110825","author":"Zhao H.","year":"2020","unstructured":"Zhao H.; Zhu Q.; Zhang C.; Li J.; Wei M.; Qin Y.; Chen G.; Wang K.; Yu J.; Wu Z.; Chen X.; Wang G.; Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size. Biomed Pharmacother 2020","journal-title":"Biomed Pharmacother"},{"key":"ref=81","unstructured":"No significant benefit of Umifenovir in COVID-19 treatment: Glenmark, Health News, ET HealthWorld. https:\/\/health.economictimes.indiatimes.com\/news\/pharma\/no-significant-benefit-of-umifenovir-in-covid-19-treatment-glenmark\/78581691"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.2147\/TCRM.S3285","volume":"4","author":"Chandwani A.","year":"2008","unstructured":"Chandwani A.; Shuter J.; Lopinavir\/ritonavir in the treatment of HIV-1 infection: A review. Ther Clin Risk Manag 2008,4(5),1023-1033","journal-title":"Ther Clin Risk Manag"},{"key":"ref=83","doi-asserted-by":"publisher","DOI":"10.1002\/3527608001","author":"Fischer J.","year":"2006","unstructured":"Fischer J.; Ganellin C.R.;  Analogue-based drug discovery 2006 http:\/\/public.ebookcentral.proquest.com\/choice\/publicfullrecord.aspx?p=481323","journal-title":"Analogue-based drug discovery"},{"key":"ref=84","author":"Sham H.L.","year":"1999","unstructured":"Sham H.L.; Norbeck D.W.; Chen X.; Betebenner D.A.;  Betebenner,\tRetroviral protease inhibiting compounds US5914332A, 1999 https:\/\/patents.google.com\/patent\/US5914332A\/en?oq=5914332","journal-title":"Betebenner,\tRetroviral protease inhibiting compounds US5914332A,"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1073\/pnas.92.7.2484","volume":"92","author":"Kempf D.J.","year":"1995","unstructured":"Kempf D.J.; Marsh K.C.; Denissen J.F.; McDonald E.; Vasavanonda S.; Flentge C.A.; Green B.E.; Fino L.; Park C.H.; Kong X.P.; ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci USA 1995,92(7),2484-2488","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=86","author":"Kempf D.J.","year":"1994","unstructured":"Kempf D.J.; Norbeck D.W.; Sham H.L.; Zhao C.; Sowin T.J.; Reno D.S.; Haight A.R.; Cooper A.J.;  Retroviral protease inhibiting\ncompounds WO1994014436A1 1994 https:\/\/patents.google.com\/patent\/WO1994014436A1\/en?oq=WO+9414436","journal-title":"Retroviral protease inhibiting\ncompounds WO1994014436A1"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1021\/jm970636+","volume":"41","author":"Kempf D.J.","year":"1998","unstructured":"Kempf D.J.; Sham H.L.; Marsh K.C.; Flentge C.A.; Betebenner D.; Green B.E.; McDonald E.; Vasavanonda S.; Saldivar A.; Wideburg N.E.; Kati W.M.; Ruiz L.; Zhao C.; Fino L.; Patterson J.; Molla A.; Plattner J.J.; Norbeck D.W.; Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy. J Med Chem 1998,41(4),602-617","journal-title":"J Med Chem"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1128\/AAC.00224-08","volume":"52","author":"Robbins B.L.","year":"2008","unstructured":"Robbins B.L.; Capparelli E.V.; Chadwick E.G.; Yogev R.; Serchuck L.; Worrell C.; Smith M.E.; Alvero C.; Fenton T.; Heckman B.; Pelton S.I.; Aldrovandi G.; Borkowsky W.; Rodman J.; Havens P.L.; PACTG 1038 Team. Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors. Antimicrob Agents Chemother 2008,52(9),3276-3283","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=89","author":"Vardanyan R.S.","year":"2016","unstructured":"Vardanyan R.S.; Hruby V.J.;  Synthesis of best-seller drugs 2016","journal-title":"Synthesis of best-seller drugs"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"4191","DOI":"10.1016\/S0040-4039(97)00866-6","volume":"38","author":"Haight A.R.","year":"1997","unstructured":"Haight A.R.; Stuk T.L.; Menzia J.A.; Robbins T.A.; A convenient synthesis of enaminones using tandem acetonitrile condensation, Grignard addition. Tetrahedron Lett 1997,38,4191-4194","journal-title":"Tetrahedron Lett"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.1021\/jo00094a006","volume":"59","author":"Stuk T.L.","year":"1994","unstructured":"Stuk T.L.; Haight A.R.; Scarpetti D.; Allen M.S.; Menzia J.A.; Robbins T.A.; Parekh S.I.; Langridge D.C.; Tien J-H.J.; An efficient stereocontrolled strategy for the synthesis of hydroxyethylene dipeptide isosteres. J Org Chem 1994,59,4040-4041","journal-title":"J Org Chem"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1055\/s-2001-18434","volume":"2001","author":"Ghosh A.K.","year":"2001","unstructured":"Ghosh A.K.; Bilcer G.; Schiltz G.; Syntheses of FDA approved HIV protease inhibitors. Synthesis (Stuttg) 2001,2001(15),2203-2229","journal-title":"Synthesis (Stuttg)"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"8739","DOI":"10.1016\/S0040-4020(01)81896-2","volume":"49","author":"Baker W.R.","year":"1993","unstructured":"Baker W.R.; Pratt J.K.; Dipeptide isosteres. 2. Synthesis of hydroxyethylene dipeptide isostere diastereomers from a common \u03b3-lactone intermediate. Preparation of renin and HIV-1 protease inhibitor transition state mimics. Tetrahedron 1993,49,8739-8756","journal-title":"Tetrahedron"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1039\/a902518i","volume":"1999","author":"Ghosh A.K.","year":"1999","unstructured":"Ghosh A.K.; Shin D.; Mathivanan P.; Asymmetric dihydroxylation route to a dipeptide isostere of a protease inhibitor: Enantioselective synthesis of the core unit of ritonavir. Chem Commun (Camb) 1999,1999(11),1025-1026","journal-title":"Chem Commun (Camb)"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S0968-0896(00)82036-2","volume":"2","author":"Kempf D.J.","year":"1994","unstructured":"Kempf D.J.; Marsh K.C.; Fino L.C.; Bryant P.; Craig-Kennard A.; Sham H.L.; Zhao C.; Vasavanonda S.; Kohlbrenner W.E.; Wideburg N.E.; Saldivar A.; Green B.E.; Herrin T.; Norbeck D.W.; Design of orally bioavailable, symmetry-based inhibitors of HIV protease. Bioorg Med Chem 1994,2(9),847-858","journal-title":"Bioorg Med Chem"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1021\/op990202j","volume":"4","author":"Stoner E.J.","year":"2000","unstructured":"Stoner E.J.; Cooper A.J.; Dickman D.A.; Kolaczkowski L.; Lallaman J.E.; Liu J-H.; Oliver-Shaffer P.A.; Patel K.M.; Paterson J.B.; Plata D.J.; Riley D.A.; Hing.L. Sham, P.J. Stengel, J.-H.J. Tien. Synthesis of HIV protease inhibitor ABT-378 (Lopinavir). Org Process Res Dev 2000,4,264-269","journal-title":"Org Process Res Dev"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1021\/op980214p","volume":"3","author":"Stoner E.J.","year":"1999","unstructured":"Stoner E.J.; Stengel P.J.; Cooper A.J.; Synthesis of ABT-378, an HIV protease inhibitor candidate: Avoiding the use of carbodiimides in a difficult peptide coupling. Org Process Res Dev 1999,3,145-148","journal-title":"Org Process Res Dev"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"8528","DOI":"10.1038\/srep08528","volume":"5","author":"Huang X.","year":"2015","unstructured":"Huang X.; Xu Y.; Yang Q.; Chen J.; Zhang T.; Li Z.; Guo C.; Chen H.; Wu H.; Li N.; Efficacy and biological safety of lopinavir\/ritonavir based anti-retroviral therapy in HIV-1-infected patients: A meta-analysis of randomized controlled trials. Sci Rep 2015,5,8528","journal-title":"Sci Rep"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/S0022-2836(03)00865-9","volume":"331","author":"Snijder E.J.","year":"2003","unstructured":"Snijder E.J.; Bredenbeek P.J.; Dobbe J.C.; Thiel V.; Ziebuhr J.; Poon L.L.M.; Guan Y.; Rozanov M.; Spaan W.J.M.; Gorbalenya A.E.; Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage. J Mol Biol 2003,331(5),991-1004","journal-title":"J Mol Biol"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1016\/j.bmc.2004.03.035","volume":"12","author":"Zhang X.W.","year":"2004","unstructured":"Zhang X.W.; Yap Y.L.; Old drugs as lead compounds for a new disease? Binding analysis of SARS coronavirus main proteinase with HIV, psychotic and parasite drugs. Bioorg Med Chem 2004,12(10),2517-2521","journal-title":"Bioorg Med Chem"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jcv.2004.03.003","volume":"31","author":"Chen F.","year":"2004","unstructured":"Chen F.; Chan K.H.; Jiang Y.; Kao R.Y.T.; Lu H.T.; Fan K.W.; Cheng V.C.C.; Tsui W.H.W.; Hung I.F.N.; Lee T.S.W.; Guan Y.; Peiris J.S.M.; Yuen K.Y.; In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol 2004,31(1),69-75","journal-title":"J Clin Virol"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1136\/thorax.2003.012658","volume":"59","author":"Chu C.M.","year":"2004","unstructured":"Chu C.M.; Cheng V.C.C.; Hung I.F.N.; Wong M.M.L.; Chan K.H.; Chan K.S.; Kao R.Y.T.; Poon L.L.M.; Wong C.L.P.; Guan Y.; Peiris J.S.M.; Yuen K.Y.; HKU\/UCH SARS Study\nGroup Role of lopinavir\/ritonavir in the treatment of SARS: Initial virological and clinical findings. Thorax 2004,59(3),252-256","journal-title":"Thorax"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.bbrc.2004.04.083","volume":"318","author":"Yamamoto N.","year":"2004","unstructured":"Yamamoto N.; Yang R.; Yoshinaka Y.; Amari S.; Nakano T.; Cinatl J.; Rabenau H.; Doerr H.W.; Hunsmann G.; Otaka A.; Tamamura H.; Fujii N.; Yamamoto N.; HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. Biochem Biophys Res Commun 2004,318(3),719-725","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"4875","DOI":"10.1128\/AAC.03011-14","volume":"58","author":"de Wilde A.H.","year":"2014","unstructured":"de Wilde A.H.; Jochmans D.; Posthuma C.C.; Zevenhoven-Dobbe J.C.; van Nieuwkoop S.; Bestebroer T.M.; van den Hoogen B.G.; Neyts J.; Snijder E.J.; Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother 2014,58(8),4875-4884","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1093\/infdis\/jiv392","volume":"212","author":"Chan J.F-W.","year":"2015","unstructured":"Chan J.F-W.; Yao Y.; Yeung M-L.; Deng W.; Bao L.; Jia L.; Li F.; Xiao C.; Gao H.; Yu P.; Cai J-P.; Chu H.; Zhou J.; Chen H.; Qin C.; Yuen K-Y.; Treatment With Lopinavir\/Ritonavir or interferon-\u03b21b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis 2015,212(12),1904-1913","journal-title":"J Infect Dis"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","volume":"382","author":"Cao B.","year":"2020","unstructured":"Cao B.; Wang Y.; Wen D.; Liu W.; Wang J.; Fan G.; Ruan L.; Song B.; Cai Y.; Wei M.; Li X.; Xia J.; Chen N.; Xiang J.; Yu T.; Bai T.; Xie X.; Zhang L.; Li C.; Yuan Y.; Chen H.; Li H.; Huang H.; Tu S.; Gong F.; Liu Y.; Wei Y.; Dong C.; Zhou F.; Gu X.; Xu J.; Liu Z.; Zhang Y.; Li H.; Shang L.; Wang K.; Li K.; Zhou X.; Dong X.; Qu Z.; Lu S.; Hu X.; Ruan S.; Luo S.; Wu J.; Peng L.; Cheng F.; Pan L.; Zou J.; Jia C.; Wang J.; Liu X.; Wang S.; Wu X.; Ge Q.; He J.; Zhan H.; Qiu F.; Guo L.; Huang C.; Jaki T.; Hayden F.G.; Horby P.W.; Zhang D.; Wang C.; A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med 2020,382(19),1787-1799","journal-title":"N Engl J Med"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1056\/NEJMe2005477","volume":"382","author":"Baden L.R.","year":"2020","unstructured":"Baden L.R.; Rubin E.J.; Covid-19 - The search for effective therapy. N Engl J Med 2020,382(19),1851-1852","journal-title":"N Engl J Med"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(20)32013-4","volume":"396","author":"Horby P.W.","year":"2020","unstructured":"Horby P.W.; Mafham M.; Bell J.L.; Linsell L.; Staplin N.; Emberson J.; Palfreeman A.; Raw J.; Elmahi E.; Prudon B.; Green C.; Carley S.; Chadwick D.; Davies M.; Wise M.P.; Baillie J.K.; Chappell L.C.; Faust S.N.; Jaki T.; Jefferey K.; Lim W.S.; Montgomery A.; Rowan K.; Juszczak E.; Haynes R.; Landray M.J.; . RECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial. Lancet 2020,396,1345-1352","journal-title":"Lancet"},{"key":"ref=109","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/jmv.25798","volume":"92","author":"Khalili J.S.","year":"2020","unstructured":"Khalili J.S.; Zhu H.; Mak N.S.A.; Yan Y.; Zhu Y.; Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19. J Med Virol 2020,92(7),740-746","journal-title":"J Med Virol"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1021\/jm00281a014","volume":"15","author":"Witkowski J.T.","year":"1972","unstructured":"Witkowski J.T.; Robins R.K.; Sidwell R.W.; Simon L.N.; Design, synthesis, and broad spectrum antiviral activity of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosides. J Med Chem 1972,15(11),1150-1154","journal-title":"J Med Chem"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1016\/j.bmc.2010.02.015","volume":"18","author":"Derudas M.","year":"2010","unstructured":"Derudas M.; Brancale A.; Naesens L.; Neyts J.; Balzarini J.; McGuigan C.; Application of the phosphoramidate ProTide approach to the antiviral drug ribavirin. Bioorg Med Chem 2010,18(7),2748-2755","journal-title":"Bioorg Med Chem"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/00304948.2012.697741","volume":"44","author":"Li Y.S.","year":"2012","unstructured":"Li Y.S.; Zhang J.J.; Mei L.Q.; Tan C.X.; An improved procedure for the preparation of ribavirin. Org Prep Proced Int 2012,44,387-391","journal-title":"Org Prep Proced Int"},{"key":"ref=113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/734851","author":"Sakharov V.","year":"2015","unstructured":"Sakharov V.; Baykov S.; Konstantinova I.; Esipov R.; Dorogov M.; An efficient chemoenzymatic process for preparation of ribavirin. Int J Chem Eng 2015,1-5","journal-title":"Int J Chem Eng"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1002\/1522-2675(200207)85:7<1901:AID-HLCA1901>3.0.CO;2-C","volume":"85","author":"Barai V.N.","year":"2002","unstructured":"Barai V.N.; Zinchenko A.I.; Eroshevskaya L.A.; Kalinichenko E.N.; Kulak T.I.; Mikhailopulo I.A.; A universal biocatalyst for the preparation of base- and sugar-modified nucleosides via an enzymatic transglycosylation. Helv Chim Acta 2002,85,1901-1908","journal-title":"Helv Chim Acta"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3109\/10242422.2010.538949","volume":"28","author":"N\u00f3bile M.","year":"2010","unstructured":"N\u00f3bile M.; Terreni M.; Lewkowicz E.; Iribarren A.M.; Aeromonas hydrophila strains as biocatalysts for transglycosylation. Biocatal Biotransform 2010,28,395-402","journal-title":"Biocatal Biotransform"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/BF03175141","volume":"59","author":"Chen N.","year":"2009","unstructured":"Chen N.; Xing C-G.; Xie X-X.; Xu Q-Y.; Optimization of technical conditions of producing ribavirin by Bacillus subtilis. Ann Microbiol 2009,59,525-530","journal-title":"Ann Microbiol"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1128\/CMR.00102-15","volume":"29","author":"De Clercq E.","year":"2016","unstructured":"De Clercq E.; Li G.; Approved antiviral drugs over the past 50 years. Clin Microbiol Rev 2016,29(3),695-747","journal-title":"Clin Microbiol Rev"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/rmv.483","volume":"16","author":"Graci J.D.","year":"2006","unstructured":"Graci J.D.; Cameron C.E.; Mechanisms of action of ribavirin against distinct viruses. Rev Med Virol 2006,16(1),37-48","journal-title":"Rev Med Virol"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"6895","DOI":"10.1073\/pnas.111085598","volume":"98","author":"Crotty S.","year":"2001","unstructured":"Crotty S.; Cameron C.E.; Andino R.; RNA virus error catastrophe: Direct molecular test by using ribavirin. Proc Natl Acad Sci USA 2001,98(12),6895-6900","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/imm.12005","volume":"137","author":"Kobayashi T.","year":"2012","unstructured":"Kobayashi T.; Nakatsuka K.; Shimizu M.; Tamura H.; Shinya E.; Atsukawa M.; Harimoto H.; Takahashi H.; Sakamoto C.; Ribavirin modulates the conversion of human CD4(+) CD25(-) T cell to CD4(+) CD25(+) FOXP3(+) T cell via suppressing interleukin-10-producing regulatory T cell. Immunology 2012,137(3),259-270","journal-title":"Immunology"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/S0168-8278(99)80093-2","volume":"30","author":"Tam R.C.","year":"1999","unstructured":"Tam R.C.; Pai B.; Bard J.; Lim C.; Averett D.R.; Phan U.T.; Milovanovic T.; Ribavirin polarizes human T cell responses towards a type 1 cytokine profile. J Hepatol 1999,30(3),376-382","journal-title":"J Hepatol"},{"key":"ref=122","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104854","volume":"157","author":"Zhang Y.","year":"2020","unstructured":"Zhang Y.; Xu Q.; Sun Z.; Zhou L.; Current targeted therapeutics against COVID-19: Based on first-line experience in China. Pharmacol Res 2020,157","journal-title":"Pharmacol Res"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1016\/j.bmcl.2017.06.074","volume":"27","author":"Wright Z.V.F.","year":"2017","unstructured":"Wright Z.V.F.; Wu N.C.; Kadam R.U.; Wilson I.A.; Wolan D.W.; Structure-based optimization and synthesis of antiviral drug Arbidol analogues with significantly improved affinity to influenza hemagglutinin. Bioorg Med Chem Lett 2017,27(16),3744-3748","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=124","author":"Wilson I.A.","year":"2018","unstructured":"Wilson I.A.;  WOLAN, DW; WRIGHT, ZVF; KADAM, RU;\nWU, NC Arbidol analogs with improved influenza hemagglutinin\npotency WO2018112128A1, 2018 https:\/\/patents.google.com\/patent\/WO2018112128A1\/en","journal-title":"WOLAN, DW; WRIGHT, ZVF; KADAM, RU;\nWU, NC Arbidol analogs with improved influenza hemagglutinin\npotency WO2018112128A1,"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/BF00772858","volume":"27","author":"Trofimov F.A.","year":"1993","unstructured":"Trofimov F.A.; Tsyshkova N.G.; Zotova S.A.; Grinev A.N.; Synthesis of a new antiviral agent, arbidole. Pharm Chem J 1993,27,75-76","journal-title":"Pharm Chem J"},{"key":"ref=126","author":"Cao Z.","year":"2012","unstructured":"Cao Z.; Dong J.; Shi L.;  Preparation method of arbidol hydrochloride\tCN102351778A, 2012 https:\/\/patents.google.com\/patent\/CN102351778A\/en","journal-title":"Preparation method of arbidol hydrochloride\tCN102351778A,"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.bmc.2005.08.041","volume":"14","author":"Chai H.","year":"2006","unstructured":"Chai H.; Zhao Y.; Zhao C.; Gong P.; Synthesis and in vitro anti-hepatitis B virus activities of some ethyl 6-bromo-5-hydroxy-1H-indole-3-carboxylates. Bioorg Med Chem 2006,14(4),911-917","journal-title":"Bioorg Med Chem"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1073\/pnas.1617020114","volume":"114","author":"Kadam R.U.","year":"2017","unstructured":"Kadam R.U.; Wilson I.A.; Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol. Proc Natl Acad Sci USA 2017,114(2),206-214","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/14651858.CD011489","author":"Huang L.","year":"2017","unstructured":"Huang L.; Zhang L.; Liu Y.; Luo R.; Zeng L.; Telegina I.; Vlassov V.V.; Arbidol for preventing and treating influenza in adults and children. Cochrane Database Syst Rev 2017,2","journal-title":"Cochrane Database Syst Rev"},{"journal-title":"Lopinavir\/ritonavir and Arbidol not effective for mild-to-moderate\nCOVID-19 Eur Pharm Rev,","key":"ref=130","unstructured":"Lopinavir\/ritonavir and Arbidol not effective for mild-to-moderate\nCOVID-19 Eur Pharm Rev,  https:\/\/www.europeanpharmaceuticalreview.com\/news\/117273\/trial-finds-lopinavir-ritonavir-and-arbidol-ineffective-for-mild-to-moderate-covid-19\/"},{"journal-title":"Favipiravir versus Arbidol for COVID-19: A Randomized Clinical\nTrial medRxiv,","key":"ref=131","unstructured":"Favipiravir versus Arbidol for COVID-19: A Randomized Clinical\nTrial medRxiv,  https:\/\/www.medrxiv.org\/content\/10.1101\/2020.03.17.20037432v4"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"4422","DOI":"10.1002\/slct.201803825","volume":"4","author":"Rapolu R.K.","year":"2019","unstructured":"Rapolu R.K.; Areveli S.; Raju V.V.N.K.V.P.; Navuluri S.; Chavali M.; Mulakayala N.; An efficient synthesis of darunavir substantially free from impurities: Synthesis and characterization of novel impurities. ChemistrySelect 2019,4,4422-4427","journal-title":"ChemistrySelect"},{"key":"ref=133","first-page":"6","author":"Babu K.R.","year":"2012","unstructured":"Babu K.R.; Rao V.K.; Sudhakar Y.; Raju C.N.; First stereoselective total synthesis of (3R, 3aS, 6aR)-hexahydrofuro[2,3-b]furan- 3-yl (2R,3S)-4-(4-amino-N-isobutyl phenylsulfonamido)-3-hydroxy-1- phenylbutan-2-yl-carbamate (diastereomer of Darunavir). Indian J Chem 2012,6","journal-title":"Indian J Chem"},{"journal-title":"Lack of evidence to support use of darunavir-based treatments for\tSARS-CoV-2 Johnson","key":"ref=134","unstructured":"Lack of evidence to support use of darunavir-based treatments for\tSARS-CoV-2 Johnson   https:\/\/www.jnj.com\/lack-of-evidence-to-support-darunavir-based-hiv-treatments-for-coronavirus"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"5723","DOI":"10.1128\/AAC.00748-11","volume":"55","author":"Dierynck I.","year":"2011","unstructured":"Dierynck I.; Van Marck H.; Van Ginderen M.; Jonckers T.H.M.; Nalam M.N.L.; Schiffer C.A.; Raoof A.; Kraus G.; Picchio G.; TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors. Antimicrob Agents Chemother 2011,55(12),5723-5731","journal-title":"Antimicrob Agents Chemother"},{"journal-title":"Chinese Clinical Trial Register (ChiCTR) - The world health organization\ninternational clinical trials registered organization registered\nplatform","key":"ref=136","unstructured":"Chinese Clinical Trial Register (ChiCTR) - The world health organization\ninternational clinical trials registered organization registered\nplatform  http:\/\/www.chictr.org.cn\/showprojen.aspx?proj=49075"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1021\/ol500583d","volume":"16","author":"Zhang Q.","year":"2014","unstructured":"Zhang Q.; Ma B-W.; Wang Q-Q.; Wang X-X.; Hu X.; Xie M-S.; Qu G-R.; Guo H-M.; The synthesis of tenofovir and its analogues via asymmetric transfer hydrogenation. Org Lett 2014,16(7),2014-2017","journal-title":"Org Lett"},{"journal-title":"Study comparing lopinavir\/ritonavir (LPV\/r) + emtricitabine\/\ntenofovir disoproxil fumarate (FTC\/TDF) with a nucleoside sparing\nregimen consisting of lopinavir\/ritonavir + raltegravir (RAL)","key":"ref=138","unstructured":"Study comparing lopinavir\/ritonavir (LPV\/r) + emtricitabine\/\ntenofovir disoproxil fumarate (FTC\/TDF) with a nucleoside sparing\nregimen consisting of lopinavir\/ritonavir + raltegravir (RAL)  https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00711009"},{"key":"ref=139","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aax5866","volume":"11","author":"Toots M.","year":"2019","unstructured":"Toots M.; Yoon J-J.; Cox R.M.; Hart M.; Sticher Z.M.; Makhsous N.; Plesker R.; Barrena A.H.; Reddy P.G.; Mitchell D.G.; Shean R.C.; Bluemling G.R.; Kolykhalov A.A.; Greninger A.L.; Natchus M.G.; Painter G.R.; Plemper R.K.; Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci Transl Med 2019,11(515)","journal-title":"Sci Transl Med"},{"journal-title":"Ridgeback biotherapeutics and drug innovations ventures at Emory\npartner to develop clinical stage coronavirus treatment","key":"ref=140","unstructured":"Ridgeback biotherapeutics and drug innovations ventures at Emory\npartner to develop clinical stage coronavirus treatment  https:\/\/www.prnewswire.com\/news-releases\/ridgeback-biotherapeutics-and-drug-innovations-ventures-at-emory-partner-to-develop-clinical-stage-coronavirus-treatment-301027190.html"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/(SICI)1099-1344(199812)41:12<1103:AID-JLCR157>3.0.CO;2-M","volume":"41","author":"Wiltshire H.R.","year":"1998","unstructured":"Wiltshire H.R.; Prior K.J.; Dhesi J.; Trach F.; Schlageter M.; Sch\u00f6nenberger H.; The synthesis of labelled forms of saquinavir. J Labelled Comp Radiopharm 1998,41,1103-1126","journal-title":"J Labelled Comp Radiopharm"},{"journal-title":"Synthesis of the HIV-proteinase inhibitor saquinavir: A\nchallenge for process research Chim Int J Chem, 1996, 50, 532-\n537","author":"G\u00f6bring W.","key":"ref=142","unstructured":"G\u00f6bring W.; Gokbale S.; Hilpert H.; Roessler F.; Schlageter M.; Vogt P.;  Synthesis of the HIV-proteinase inhibitor saquinavir: A\nchallenge for process research Chim Int J Chem, 1996, 50, 532-\n537  https:\/\/www.ingentaconnect.com\/content\/scs\/chimia\/1996\/00000050\/00000011\/art00007"},{"key":"ref=143","unstructured":"https:\/\/iris.paho.org\/bitstream\/handle\/10665.2\/52025\/PAHOIMSCovid19200008_eng.pdf?sequence=1"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/nature13027","volume":"508","author":"Warren T.K.","year":"2014","unstructured":"Warren T.K.; Wells J.; Panchal R.G.; Stuthman K.S.; Garza N.L.; Van Tongeren S.A.; Dong L.; Retterer C.J.; Eaton B.P.; Pegoraro G.; Honnold S.; Bantia S.; Kotian P.; Chen X.; Taubenheim B.R.; Welch L.S.; Minning D.M.; Babu Y.S.; Sheridan W.P.; Bavari S.; Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 2014,508(7496),402-405","journal-title":"Nature"},{"journal-title":"BioCryst completes phase 1 clinical trial of Galidesivir | BioCryst\tPharmaceuticals","key":"ref=145","unstructured":"BioCryst completes phase 1 clinical trial of Galidesivir | BioCryst\tPharmaceuticals  http:\/\/ir.biocryst.com\/news-releases\/news-release-details\/biocryst-completes-phase-1-clinical-trial-galidesivir"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/9780470929353.ch18","author":"Seiwert S.D.","year":"2011","unstructured":"Seiwert S.D.; Kossen K.; Pan L.; Liu J.; Buckman B.O.;  Discovery and development of the HCV NS3\/4A protease inhibitor Danoprevir (ITMN-191\/RG7227) Antivir Drugs 2011,257-271","journal-title":"Discovery and development of the HCV NS3\/4A protease inhibitor Danoprevir (ITMN-191\/RG7227) Antivir Drugs"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1021\/jm400164c","volume":"57","author":"Jiang Y.","year":"2014","unstructured":"Jiang Y.; Andrews S.W.; Condroski K.R.; Buckman B.; Serebryany V.; Wenglowsky S.; Kennedy A.L.; Madduru M.R.; Wang B.; Lyon M.; Doherty G.A.; Woodard B.T.; Lemieux C.; Geck Do M.; Zhang H.; Ballard J.; Vigers G.; Brandhuber B.J.; Stengel P.; Josey J.A.; Beigelman L.; Blatt L.; Seiwert S.D.; Discovery of danoprevir (ITMN-191\/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3\/4A protease. J Med Chem 2014,57(5),1753-1769","journal-title":"J Med Chem"},{"journal-title":"Efficacy and safety of Ganovo (Danoprevir) combined with ritonavir\nin the treatment of SARS-CoV-2 infection","key":"ref=148","unstructured":"Efficacy and safety of Ganovo (Danoprevir) combined with ritonavir\nin the treatment of SARS-CoV-2 infection  https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04345276"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.1021\/acs.orglett.5b00982","volume":"17","author":"Caso M.F.","year":"2015","unstructured":"Caso M.F.; D\u2019Alonzo D.; D\u2019Errico S.; Palumbo G.; Guaragna A.; Highly stereoselective synthesis of lamivudine (3TC) and emtricitabine (FTC) by a novel N-glycosidation procedure. Org Lett 2015,17(11),2626-2629","journal-title":"Org Lett"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1002\/slct.201700052","volume":"2","author":"Mandala D.","year":"2017","unstructured":"Mandala D.; Watts P.; An improved synthesis of lamivudine and emtricitabine. ChemistrySelect 2017,2,1102-1105","journal-title":"ChemistrySelect"}],"container-title":["Mini-Reviews in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389557521666201222145842","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/189357\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389557521666201222145842","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,14]],"date-time":"2022-08-14T07:58:56Z","timestamp":1660463936000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/189357\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":150,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389557521666201222145842","relation":{},"ISSN":["1389-5575"],"issn-type":[{"type":"print","value":"1389-5575"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-07-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-28","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}